Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid l...
Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia
About this item
Full title
Author / Creator
Publisher
Singapore: Springer Singapore
Journal title
Language
English
Formats
Publication information
Publisher
Singapore: Springer Singapore
Subjects
More information
Scope and Contents
Contents
This open-label, single-arm, phase 2 study (ClinicalTrials.gov, NCT03128411) evaluated the efficacy, safety, and pharmacokinetics of bosutinib at a starting dose of 400 mg once daily (QD) in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML). The primary endpoint was major molecular response (MMR) at Month 12 in...
Alternative Titles
Full title
Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2413838997
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2413838997
Other Identifiers
ISSN
0925-5710
E-ISSN
1865-3774
DOI
10.1007/s12185-020-02878-x
